Randomized Trial of [131I] Metuximab in Treatment of Hepatocellular Carcinoma After Percutaneous Radiofrequency Ablation-Reference-Cited by-同舟云学术

Randomized Trial of [131I] Metuximab in Treatment of Hepatocellular Carcinoma After Percutaneous Radiofrequency Ablation

Published:2014-09 Issue:9 Volume:106 Page:
ISSN:1460-2105
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Bian Huijie,Zheng Jia-Sheng,Nan Gang,Li Rui,Chen Changsheng,Hu Cai-Xia,Zhang Yang,Sun Bin,Wang Xi-Long,Cui Shi-Chang,Wu Jiao,Xu Jing,Wei Ding,Zhang Xiaoyong,Liu Haichun,Yang Wuwei,Ding Yong,Li Jing,Chen Zhi-Nan

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/106/9/dju239/17313716/dju239.pdf

Reference16 articles.

1. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma;Omata;Hepatol Int,2010

2. Management of hepatocellular carcinoma: an update;Bruix;Hepatology,2011

3. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma;J Hepatol,2012

4. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial;Peng;Radiology,2012

5. Radiofrequency ablation of recurrent hepatocellular carcinoma in a patient after liver transplantation: two-year follow-up;Ho;J Vasc Interv Radiol,2007

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD147 facilitates cisplatin resistance in ovarian cancer through FOXM1 degradation inhibition;Genes & Diseases;2024-09

2. Alarmin S100A8 imparts chemoresistance of esophageal cancer by reprogramming cancer-associated fibroblasts;Cell Reports Medicine;2024-06

3. Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time?;Current Oncology;2024-05-31

4. Hypoxia‐activated ADCC‐enhanced humanized anti‐CD147 antibody for liver cancer imaging and targeted therapy with improved selectivity;MedComm;2024-03

5. Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis;Health Technology Assessment;2023-12